Browse studies
Find your next paid study
2 recruiting studies matching your filters
Phase 1
Mercaptopurine (6-MP) for the Treatment of Manifestations of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC)
This phase I/II trial studies the side effects and best dose of mercaptopurine, and to see how well it works in treating patients with hereditary leiomyomatosi…
Advanced Kidney CarcinomaAdvanced Renal Cell CarcinomaHereditary Leiomyomatosis and Renal Cell Carcinoma+6 more
Estimated
~$10 – $6,250
Jonsson Comprehensive Cancer CenterNCT07716735
Phase 2
A Phase 2 Study of Bevacizumab, Erlotinib and Atezolizumab in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) Associated or Sporadic Papillary Renal Cell Cancer
This phase II trial studies the effects of combination therapy with bevacizumab, erlotinib, and atezolizumab in treating patients with hereditary leiomyomatosi…
Hereditary Leiomyomatosis and Renal Cell CarcinomaPapillary Renal Cell CarcinomaRenal Cell Carcinoma+3 more
Estimated
~$10 – $5,625
National Cancer Institute (NCI)NCT04981509